New therapies towards a better glycemic control in youths with type 1 diabetes

Cardona-Hernández, Roque; Dovč, Klemen; Biester, Torben; Ekhlaspour, Laya; Macedoni, Maddalena; Tauschmann, Martin; Mameli, Chiara

doi:10.1016/j.phrs.2023.106882

Cited by 2 publications

(1 citation statement)

References 102 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even withdrawn from the market (Drucker et al, 2010;Blonde et al, 2022;Röder et al, 2016). Among all the adjunctive therapies tested for T1D, the most promising approach currently appears to be the SGLT2i, which provide an insulin-independent approach to lower plasma glucose (Cardona-Hernandez et al, 2023). Overall results with these drugs present greater reductions of HbA1c and weight (Langford et al, 2020), although they significantly increase the risk of diabetes ketoacidosis (Garcia-Tirado et al, 2022).…”

Section: Glitazones (Pioglitazone Trosiglitazone Rosiglitazone)mentioning

confidence: 99%

Contributions to glucagon and pramlintide pharmacokinetics and pharmacodynamics modeling for multi-hormone artificial pancreas systems

Furió Novejarque

View full text Add to dashboard Cite

show abstract

Section: Glitazones (Pioglitazone Trosiglitazone Rosiglitazone)mentioning

confidence: 99%

Contributions to glucagon and pramlintide pharmacokinetics and pharmacodynamics modeling for multi-hormone artificial pancreas systems

Furió Novejarque

View full text Add to dashboard Cite

show abstract

Current Pharmacological Treatments in Type 1 Diabetes and Patient Tolerability Against New Generation Medicines

Serdar Deniz

2024

Type 1 Diabetes - Causes, Symptoms, and Treatments [Working Title]

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1D) is an autoimmune condition characterized by insulin deficiency due to pancreatic beta-cell destruction. The global incidence of T1D has been increasing and reached 12 million patients in 2021. Diabetes is expected to rank third place, following cardiovascular disease and stroke within factors that reduce life expectancy. T1D patients suffer from poor glycemic control due to fluctuations in glucose levels, leading to cardiovascular disease, nephropathy, and retinopathy. T1D currently has no cure, and management strategies are crucial for improving the quality of patient life. In this chapter, we will be discussing advancements in diabetes technologies, focusing on management and emerging therapies. Newer technologies in glucose monitoring, better analogs for insulin replacement therapies, and advanced continuous subcutaneous insulin infusion (CSII) devices eliminating the burden of manual multiple daily injections (MDI) are proving to be beneficial to diabetics. Additionally, combined adjunct therapies where amylin analogs, GLP-1 receptor agonists, and SGLT2 inhibitors, as well as emerging immunotherapy, offer complementary benefits in managing T1D. Although surgical interventions such as the pancreas or islet transplantations are currently applied as a necessary measure to rescue organ failure, advancements in stem cell technologies and synthetic biology eliminate donor requirements and increase the survival of transplants.

show abstract

New therapies towards a better glycemic control in youths with type 1 diabetes

Cited by 2 publications

References 102 publications

Contributions to glucagon and pramlintide pharmacokinetics and pharmacodynamics modeling for multi-hormone artificial pancreas systems

Contributions to glucagon and pramlintide pharmacokinetics and pharmacodynamics modeling for multi-hormone artificial pancreas systems

Current Pharmacological Treatments in Type 1 Diabetes and Patient Tolerability Against New Generation Medicines

Contact Info

Product

Resources

About